Quick Take
- Narration: Will Damron delivers a measured, journalistic tone that suits the material perfectly, he doesn’t inflate the drama, because the story doesn’t need it.
- Themes: Corporate fraud and Silicon Valley hubris, the failure of institutional oversight, the cost of silence
- Mood: Tense and methodical, with the pacing of investigative journalism done right
- Verdict: One of the strongest true-crime/business investigations of the decade, and Will Damron’s narration keeps the complexity accessible across nearly twelve hours.
I was on a flight to a publishing conference when I started Bad Blood, and I missed the in-flight meal because I didn’t want to put my headphones down. I had followed the Theranos story in the news as it unraveled, the Wall Street Journal investigations, the SEC charges, the eventual criminal conviction, but I hadn’t understood, until John Carreyrou laid it out chapter by chapter, just how many things had to fail simultaneously for Elizabeth Holmes to maintain her fraud for as long as she did. By the time I landed, I had two hours left and finished them on the train home.
Carreyrou is a Wall Street Journal reporter who broke the Theranos story through a series of investigations that required years of source cultivation, legal pressure, and genuine physical courage. The book is the full account: how Holmes built Theranos, how the technology failed from its earliest stages, how she and her partner Sunny Balwani silenced employees, intimidated journalists, and enlisted powerful allies to keep the fiction alive. The story is extraordinary on its face, a company valued at $9 billion whose core technology, a device that claimed to run hundreds of lab tests from a single drop of blood, simply did not work, but Carreyrou’s achievement is making it feel inevitable in retrospect, and genuinely baffling in real time.
Our Take on Bad Blood
What elevates this above standard corporate scandal reporting is Carreyrou’s access and precision. He names names, documents specific deceptions, and follows individual employees, scientists, lab technicians, executives, whose internal warnings were suppressed or ignored. The human cost is not abstract. Patients received erroneous test results. Diagnoses were made on faulty data. The gap between what Theranos was claiming and what its machines could actually do was not a matter of ambition outpacing technology; it was knowing fraud, maintained through aggressive legal threats and the deliberate exploitation of investor credulity.
Holmes herself is rendered with complex and chilling clarity. Carreyrou neither reduces her to a cartoon villain nor extends the sympathy that some narratives have offered. She was brilliant, charismatic, and fully aware of what she was doing. The Steve Jobs comparisons that media lavished on her, the black turtlenecks, the Stanford dropout mythology, the reality-distortion field, are examined as both marketing strategy and genuine psychological phenomenon.
Why Listen to This Rather Than Read It
Will Damron’s narration is an excellent match for investigative journalism in audio form. He reads with the measured, deliberate tone of a reporter presenting evidence, no melodrama, no performative outrage, which actually intensifies the impact. The story is so outrageous that restraint is the right choice. When Damron describes the moment Holmes silences a concerned employee, or the sequence in which investors and board members failed to ask the questions they should have, the flat reportorial delivery makes the wrongness land harder than theatrical narration would.
At nearly twelve hours, this is a substantial listen, but the structure keeps it engaging throughout. Carreyrou organizes the story chronologically with occasional departures to trace a specific character’s arc, and Damron navigates these shifts cleanly. The afterword, which addresses events after the original publication, is included and adds genuine value.
What to Watch For in Bad Blood
This is a book about American venture capital, Silicon Valley culture, and the specific dynamics of a startup ecosystem that rewards audacity over accountability. Listeners unfamiliar with that context will absorb it through the narrative without difficulty, but it helps to know going in that the story is partly about an environment that was structurally primed to believe in Holmes. The investors, the board members, the media figures who promoted Theranos without verification, they are not purely naive. They were operating within a culture that had trained itself to celebrate disruption and distrust skepticism.
The genre classification in this listing as education/learning is somewhat misleading. This is investigative journalism and true crime in the most rigorous sense, it belongs alongside books like Bryan Burrough’s Barbarians at the Gate or Michael Lewis’s best work, not in a general learning category. Do not let the genre label steer you away if you came here from a business or nonfiction interest.
Who Should Listen to Bad Blood
Anyone with an interest in corporate accountability, investigative journalism, startup culture, or the specific question of how fraud sustains itself in plain sight will find this essential. Business readers who want to understand how due diligence failed systemically will find specific, documented examples. Listeners who enjoyed The Dropout podcast or the HBO documentary and want the full reported account should know this is where those narratives drew from.
If you prefer your nonfiction narrative to offer redemptive conclusions or clear answers about what could have been done differently, the ending is somewhat open, justice arrived slowly and partially. But if you want the story fully told, with sources, consequences, and genuine moral clarity about who did what and why, this is the definitive account.
Frequently Asked Questions
Does this audiobook include the afterword covering Elizabeth Holmes’ criminal trial and conviction?
The edition listed here (2018) includes an afterword covering events after the original publication. The criminal conviction came in 2022, which postdates this edition. Listeners wanting the full arc through trial and sentencing will need to supplement with journalism or a later edition, but the core fraud investigation is comprehensively covered here.
How does Will Damron’s narration handle the large cast of characters, scientists, executives, investors, journalists?
Damron uses a consistent, measured register across all characters rather than adopting distinct voices, which suits the journalistic nature of the book. The characters are differentiated through the writing rather than through vocal performance, and Damron navigates the large cast cleanly without making the listener work to track who is speaking.
Is this book appropriate for listeners without a background in medicine or laboratory science?
Yes. Carreyrou explains the relevant medical and laboratory context as he goes, what blood tests actually require, why Theranos’s claims were technically implausible, what regulatory oversight should have caught. You don’t need specialized knowledge. The book is written for a general audience and was reviewed on its merits by readers across backgrounds, including one who described it as gripping despite having no prior connection to healthcare.
How does this compare to the HBO documentary about Theranos as a way to engage with the story?
The documentary draws heavily on this book and covers the high-level arc compellingly, but Carreyrou’s account is substantially more detailed on the internal mechanics of the fraud, specific employees who were threatened, specific investors who failed to ask obvious questions, specific test failures that were covered up. Readers who found the documentary compelling will get considerably more depth and documentation from the audio.
